KHENERFIN is a Phase 3 study investigating whether sonlicromanol improves fatigue (lack of energy), muscle weakness, and other symptoms in people living with m.3243A>G PMD, including classic MELAS, MIDD and Mixed Phenotypes.
KHENERFIN is a blinded, placebo-controlled study in which half of the patients will receive sonlicromanol and the other half placebo. The first wave of the study will include 40 participants; the second will include an additional 110 participants.
First wave study locations can be found here
Door-to-door travel support for participants
At-home assesments and potential for at-home study visits
Half of the participants will receive sonlicromanol
Access to sonlicromanol for all participants in a planned compassionate use program
Sonlicromanol is an investigational medicine that is taken as a twice-a-day oral tablet. Sonlicromanol has been studied in a Phase 1 study in healthy volunteers, in three studies (KHENERGY, KHENERGYZE AND KHENEREXT) in participants with m.3243A>G PMD and in one study (KHENERGYC) in children with PMD. A Named Patient Program with up to 2½ years favorable safety data is ongoing.
KH stands for Khondrion who’s aim is to bring ENERGY back to patients. FIN stand for FINAL meaning that this study being the last study before market authorization.
To be considered for participation in KHENERFIN, the individuals must:
Final eligibility will be determined by the study doctor.
To learn more about KHENERFIN, contact study staff directly using the contact information provided on clinicaltrials.gov [NCT06451757] or email khenerfin@khondrion.com.
